Celldex Therapeutics, Inc. Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations

NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin® in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the “ReACT Study.” This new study will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopepimut in patients with newly diagnosed EGFRvIII-expressing glioblastoma (GB).